Generation of an Induced Pluripotent Stem Cell‐Derived Alveolar Type II In Vitro Model to Study Influenza A Virus Infection and Drug Treatments
Source abstract
Abstract
ABSTRACT Influenza viruses (IVs) represent a significant global health issue, capable of causing seasonal epidemics and occasional pandemics with substantial morbidity and mortality. The emergence of viral resistance further complicates treatment strategies. In this study, induced pluripotent stem cell‐derived human alveolar type II (iAT2) cells are used to model influenza A virus (IAV) infection and to assess antiviral responses. Cultured at an air–liquid interface (ALI) in transwell systems, iAT2 cells recapitulate key features of the alveolar epithelium and support productive IAV replication. Upon infection, iAT2 cells mounted an antiviral transcriptional response and exhibited sensitivity to oseltamivir treatment, consistent with its established in vivo efficacy. Together, these findings highlight the utility of iAT2 cells as a scalable, physiologically relevant in vitro model for influenza research and antiviral drug testing. Future applications may include the evaluation of emerging viral strains and the development of personalized antiviral therapies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Respiratory viral infections research · Influenza Virus Research Studies · Neonatal Respiratory Health Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Applied Optics and Biophysics Friedrich Schiller University Jena Germany
Department Biophysical Imaging Leibniz Institute of Photonic Technology Jena Germany
Section of Experimental Virology Institute of Medical Microbiology Jena University Hospital Jena Germany
Institute Biochemistry II Research Group Non‐Animal Methods in Infection and Inflammation Research Jena University Hospital Jena Germany
Research Group Applied Systems Biology Leibniz Institute for Natural Product Research and Infection Biology – Hans‐Knöll‐Institute Jena Germany
Faculty of Biological Sciences Friedrich Schiller University Jena Germany
Center For Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven the Netherlands
Institute of Microbiology Faculty of Biological Sciences Friedrich Schiller University Jena Germany
Funding
Deutsche Forschungsgemeinschaft · H2020 European Institute of Innovation and Technology · Leibniz-Gemeinschaft
References (100+)
Show source-provided references
1. 10.7189/jogh.09.02042110.7189/jogh.09.020421 ↗
2. 10.1016/S0140-6736(17)33293-210.1016/S0140-6736(17)33293-2 ↗
3. WHO Vol.2024 World Health Organization (WHO) WHO webpage(2023) https://www.who.int/news‐room/fact‐sheets/detail/influenza‐(seasonal).
4. 10.1038/s41572-018-0002-y10.1038/s41572-018-0002-y ↗
5. ECDC Vol.2024 European Centre for Disease Prevention and Control (ECDC) ECDC webpage (2022) https://www.ecdc.europa.eu/en/seasonal‐influenza/prevention‐and‐control/antivirals.
6. CDC Vol.2024 Centers for Disease Control and Prevention (CDC) CDC webpage (2023) https://www.cdc.gov/flu/about/viruses‐types.html.
7. 10.1038/s41579-021-00542-710.1038/s41579-021-00542-7 ↗
8. 10.1080/21505594.2023.222305710.1080/21505594.2023.2223057 ↗
9. 10.4049/jimmunol.210029410.4049/jimmunol.2100294 ↗
10. 10.1371/journal.pone.003821410.1371/journal.pone.0038214 ↗
11. 10.3389/fimmu.2021.63329710.3389/fimmu.2021.633297 ↗
12. 10.3389/fimmu.2017.0142310.3389/fimmu.2017.01423 ↗
13. 10.1126/science.abc206110.1126/science.abc2061 ↗
14. 10.1086/65058110.1086/650581 ↗
15. WHO Vol.2024 World Health Organization (WHO) WHO webpage(2019) https://www.who.int/news/item/11‐03‐2019‐who‐launches‐new‐global‐influenza‐strategy.
16. 10.1093/infdis/jiv57910.1093/infdis/jiv579 ↗
17. Vaccines for Preventing Influenza in Healthy Adults
18. 10.3389/fimmu.2022.87894310.3389/fimmu.2022.878943 ↗
19. WHO Vol.2024 World Health Organization (WHO) WHO webpage(2018) https://www.who.int/europe/news‐room/fact‐sheets/item/influenza‐vaccination‐coverage‐and‐effectiveness.
20. ECDC Vol.2024 European Centre for Disease Prevention and Control (ECDC) ECDC webpage(2023) https://www.ecdc.europa.eu/en/seasonal‐influenza/facts/questions‐and‐answers‐seasonal‐influenza.
21. 10.1038/cmi.2015.7410.1038/cmi.2015.74 ↗
22. 10.1016/j.antiviral.2018.01.00210.1016/j.antiviral.2018.01.002 ↗
23. 10.1093/cid/ciy86610.1093/cid/ciy866 ↗
24. 10.1007/s10096-016-2611-210.1007/s10096-016-2611-2 ↗
25. 10.1097/MCP.000000000000037810.1097/MCP.0000000000000378 ↗
26. 10.3390/v1306101110.3390/v13061011 ↗
27. 10.1002/2211-5463.1341610.1002/2211-5463.13416 ↗
28. 10.1038/s41586-021-03365-x10.1038/s41586-021-03365-x ↗
29. 10.1126/scitranslmed.abo216710.1126/scitranslmed.abo2167 ↗
30. 10.1016/j.celrep.2022.11045610.1016/j.celrep.2022.110456 ↗
31. 10.1111/irv.1276010.1111/irv.12760 ↗
32. 10.1016/j.cell.2023.08.01110.1016/j.cell.2023.08.011 ↗
33. 10.1002/iid3.30310.1002/iid3.303 ↗
34. 10.21873/invivo.1222110.21873/invivo.12221 ↗
35. 10.3390/v1212140710.3390/v12121407 ↗
36. 10.1371/journal.ppat.100859210.1371/journal.ppat.1008592 ↗
37. 10.1128/JVI.01421-2110.1128/JVI.01421-21 ↗
38. 10.3390/ph1204014710.3390/ph12040147 ↗
39. 10.3390/challe901000210.3390/challe9010002 ↗
40. 10.1080/22221751.2023.221168510.1080/22221751.2023.2211685 ↗
41. 10.1016/j.crmeth.2022.10031410.1016/j.crmeth.2022.100314 ↗
42. 10.1038/nrm.2015.2710.1038/nrm.2015.27 ↗
43. 10.1002/adma.20190200510.1002/adma.201902005 ↗
44. 10.1186/s40824-023-00382-x10.1186/s40824-023-00382-x ↗
45. 10.1038/nprot.2015.02310.1038/nprot.2015.023 ↗
46. 10.1172/JCI8995010.1172/JCI89950 ↗
47. 10.1128/mBio.00276-1610.1128/mBio.00276-16 ↗
48. 10.1016/j.biocel.2013.08.00910.1016/j.biocel.2013.08.009 ↗
49. 10.1093/infdis/jis45510.1093/infdis/jis455 ↗
50. 10.3389/fimmu.2024.132845310.3389/fimmu.2024.1328453 ↗
51. 10.1128/JVI.76.7.3544-3553.200210.1128/JVI.76.7.3544-3553.2002 ↗
52. Human iPSC‐Derived Alveolar and Airway Epithelial Cells Can Be Cultured at Air–Liquid Interface and Express SARS‐CoV‐2 Host Factors
53. 10.1172/jci.insight.15558910.1172/jci.insight.155589 ↗
54. 10.1016/j.ejpb.2023.01.01310.1016/j.ejpb.2023.01.013 ↗
55. 10.1002/anbr.20200011110.1002/anbr.202000111 ↗
56. 10.18632/oncotarget.2320810.18632/oncotarget.23208 ↗
57. 10.3389/fmicb.2018.0320410.3389/fmicb.2018.03204 ↗
58. 10.1038/s41596-019-0220-010.1038/s41596-019-0220-0 ↗
59. 10.3390/ijms2110370810.3390/ijms21103708 ↗
60. 10.1074/jbc.M21090920010.1074/jbc.M210909200 ↗
61. 10.1016/j.celrep.2021.10963610.1016/j.celrep.2021.109636 ↗
62. 10.1016/j.crtox.2022.10010110.1016/j.crtox.2022.100101 ↗
63. 10.1016/j.micinf.2006.04.00910.1016/j.micinf.2006.04.009 ↗
64. 10.1172/JCI3806110.1172/JCI38061 ↗
65. 10.1152/ajplung.00337.201510.1152/ajplung.00337.2015 ↗
66. 10.1165/rcmb.2020-0259OC10.1165/rcmb.2020-0259OC ↗
67. 10.1186/s13059-024-03243-510.1186/s13059-024-03243-5 ↗
68. 10.1038/s41598-020-62226-110.1038/s41598-020-62226-1 ↗
69. 10.1172/JCI6878210.1172/JCI68782 ↗
70. 10.1165/rcmb.2013-0497OC10.1165/rcmb.2013-0497OC ↗
71. 10.1038/333426a010.1038/333426a0 ↗
72. Sialic Acid Receptors of Viruses
73. 10.1016/S0021-9258(19)75677-410.1016/S0021-9258(19)75677-4 ↗
74. 10.1016/0003-9861(87)90074-910.1016/0003-9861(87)90074-9 ↗
75. 10.1016/S0021-9258(18)68821-010.1016/S0021-9258(18)68821-0 ↗
76. 10.1093/glycob/cwr08010.1093/glycob/cwr080 ↗
77. 10.1038/s41586-020-3014-110.1038/s41586-020-3014-1 ↗
78. 10.1016/j.celrep.2025.11584210.1016/j.celrep.2025.115842 ↗
79. 10.1371/journal.pone.006845010.1371/journal.pone.0068450 ↗
80. 10.1016/j.antiviral.2013.07.01810.1016/j.antiviral.2013.07.018 ↗
81. 10.1128/iai.7.3.341-351.197310.1128/iai.7.3.341-351.1973 ↗
82. 10.1016/j.isci.2022.10403710.1016/j.isci.2022.104037 ↗
83. 10.1038/s41598-022-24792-410.1038/s41598-022-24792-4 ↗
84. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
85. 10.4161/spmg.1988510.4161/spmg.19885 ↗
86. 10.1038/s41598-021-94095-710.1038/s41598-021-94095-7 ↗
87. 10.1038/sj.onc.120555010.1038/sj.onc.1205550 ↗
88. 10.1016/0014-4827(61)90192-610.1016/0014-4827(61)90192-6 ↗
89. 10.1016/j.stem.2020.09.01310.1016/j.stem.2020.09.013 ↗
90. 10.1073/pnas.180630811510.1073/pnas.1806308115 ↗
91. 10.1038/s12276-021-00629-410.1038/s12276-021-00629-4 ↗
92. 10.1038/s44298-024-00017-510.1038/s44298-024-00017-5 ↗
93. 10.1183/13993003.01282-201510.1183/13993003.01282-2015 ↗
94. 10.1186/1465-9921-10-10210.1186/1465-9921-10-102 ↗
95. 10.1128/JVI.00384-0610.1128/JVI.00384-06 ↗
96. 10.1165/rcmb.2010-0108OC10.1165/rcmb.2010-0108OC ↗
97. 10.1016/j.celrep.2020.10780110.1016/j.celrep.2020.107801 ↗
98. 10.1038/s42003-022-03131-310.1038/s42003-022-03131-3 ↗
99. 10.1186/s12967-024-05376-410.1186/s12967-024-05376-4 ↗
100. 10.1093/infdis/jiaf47010.1093/infdis/jiaf470 ↗